NCT05053321View on ClinicalTrials.gov

Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

October 18, 2024

Primary Completion Date

October 18, 2025

Study Completion Date

October 18, 2025

Conditions

Tardive Dyskinesia

Interventions

DRUG

Valbenazine

All participants will be treated with Valbenazine for 6 weeks.

Trial Locations (1)

06520

Yale Church Street Research Unit., New Haven

Sponsors

Collaborators (1)

Neurocrine Biosciences

All Listed Sponsors

collaborator

Neurocrine Biosciences

INDUSTRY

lead

Yale University

OTHER